Imatinib (IM) 400 mg is the standard treatment for Chronic Myeloid Leukemia (CML) in early Chronic Phase (ECP): the results of the IRIS trial have shown for the IM arm a Complete Cytogenetic Response (CCgR) 12-months probability of 69%, with different CCgR rates according to Sokal score (76%, 67% and 49% in low, intermediate and high risk, respectively). At 84 months, overall survival (OS), event-free survival (EFS) and progression-free survival (PFS) were 86%, 81% and 93%, respectively. The outcome was significantly influenced by the Sokal score, but, once the CCgR was obtained, the relative risk did not influenced the probability of subsequent progression. Aims. To investigate the response to imatinib and the long-term outcome, overall and by Sokal Risk, of Ph+ CML patients in ECP.
RESPONSE TO IMATINIB AND LONG-TERM OUTCOME IN EARLY CHRONIC PHASE CML: THE GIMEMA CML WORKING PARTY EXPERIENCE ON 559 PATIENTS
CAVAZZINI, Francesco;
2009
Abstract
Imatinib (IM) 400 mg is the standard treatment for Chronic Myeloid Leukemia (CML) in early Chronic Phase (ECP): the results of the IRIS trial have shown for the IM arm a Complete Cytogenetic Response (CCgR) 12-months probability of 69%, with different CCgR rates according to Sokal score (76%, 67% and 49% in low, intermediate and high risk, respectively). At 84 months, overall survival (OS), event-free survival (EFS) and progression-free survival (PFS) were 86%, 81% and 93%, respectively. The outcome was significantly influenced by the Sokal score, but, once the CCgR was obtained, the relative risk did not influenced the probability of subsequent progression. Aims. To investigate the response to imatinib and the long-term outcome, overall and by Sokal Risk, of Ph+ CML patients in ECP.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
